Monte Rosa Therapeutics

Research Associate, Automation & Screening (6 Month Contract)

Monte Rosa Therapeutics  •  Boston, MA (Onsite)  •  11 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.
43
AI Success™

Job Description

Monte Rosa Therapeutics is seeking a motivated Contract Research Associate for 6 months to contribute to our mission of eliminating disease-causing proteins through targeted protein degradation, an innovative approach that enables us to target proteins once considered undruggable. The ideal candidate will have strong expertise in Cell and Molecular Biology, utilizing CRISPR techniques in a drug discovery setting. You will join a fast-paced and innovative team environment that values teamwork, collaboration, and scientific rigor.

Responsibilities

  • Engineer mammalian cell lines by CRISPR technology (KI and KO) and lentiviral transduction.
  • Culture a variety of cell lines and primary cells, testing compound-induced target degradation by Western Blot, JESS and plate-based assays
  • Assess pathway modulation by using pharmacological and genetic target perturbation strategies.
  • Keep meticulous records of experiments on ELN.

Qualifications

• B.S. or M.S. in Biotechnology, Molecular Biology, Genetics or related field with 1-3 years of industry experience.• Extensive experience with cell culture techniques including transient transfection, lentiviral transduction, CRISPR, NanoBiT and NanoBRET. Experience handling primary cells desired.• Experience with molecular biology techniques (ELISAs, Western Blot, PCR, vector design, sequencing analysis).• Immunology background is a plus.• Previous experience with lab automation and high throughput data management, analysis and visualization (e.g. Spotfire, CDD Vault, Genedata) is a plus.• Excellent oral and written communication skills.

Monte Rosa Therapeutics

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.

Industry
Biotech & Life Sciences
Company Size
201-500 employees
Headquarters
Boston, Massachusetts
Year Founded
Unknown
Social Media